Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta-analysis

Thu Apr 18 23:27:15 2024

(2022) Comparison of visfatin levels in patients with breast cancer and endometrial cancer with healthy individuals: A systematic review and meta-analysis. Health Science Reports. p. 6.

Full text not available from this repository.

Official URL: <Go to ISI>://WOS:000888024400001

Abstract

Background and aimsEndometrial cancer (EC) and breast cancer (BC) are prevalent in women. Visfatin is an adipokine that, in addition to being involved in metabolism and inflammation, may also be interested in carcinogenesis. Visfatin measurement in cancer patients has shown that visfatin levels in cancer patients differed from those in healthy subjects. Various studies have shown that the level of visfatin is increased in people within EC and BC, and this difference has a significant relationship with prognosis. MethodsA comprehensive search of related articles from PubMed, Scopus, Web of Science, and the Google Scholar database was done by November 2021. Eligible articles measured visfatin levels in patients with breast cancer and EC. After selecting the eligible studies, the data were extracted and analyzed using the random effect method. ResultsGiven the effect size and the confidence interval obtained, the total level of visfatin in cancer patients was different from that in healthy individuals, and this difference was statistically significant. However, the difference in visfatin levels in patients with breast cancer was much more significant than in patients with EC compared to the control group. ConclusionsDue to the significant increase in visfatin levels in these patients, visfatin may be a potential prognostic factor in breast and ECs. Visfatin levels in cancer patients differed from those in healthy subjects, and this difference was also statistically significant (p-values = 0.00). Visfatin levels also differed between breast cancer patients and healthy individuals, which was statistically significant (p-values = 0.00). The difference in visfatin levels between patients with EC and healthy subjects was statistically significant (p-values = 0.047).

Item Type: Article
Creators:
CreatorsEmail
Ghaneialvar, H.UNSPECIFIED
Shiri, S.UNSPECIFIED
Kenarkoohi, A.UNSPECIFIED
Vastani, Z. F.UNSPECIFIED
Ahmadi, A.UNSPECIFIED
Khorshidi, A.UNSPECIFIED
Khooz, R.UNSPECIFIED
Keywords: adipokine breast cancer (BC) endometrial cancer (EC) neoplasm nicotinamide phosphoribosyltransferase (NAMPT) visfatin potential biomarker risk adipokines resistin prostate Public, Environmental & Occupational Health General & Internal Medicine
Divisions:
Page Range: p. 6
Journal or Publication Title: Health Science Reports
Journal Index: ISI
Volume: 5
Number: 6
Identification Number: https://doi.org/10.1002/hsr2.895
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/4165

Actions (login required)

View Item View Item